BeiGene, Ltd.

NasdaqGS:BGNE 주식 보고서

시가총액: US$23.2b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

BeiGene 관리

관리 기준 확인 2/4

BeiGene's CEO는 John Oyler, Jan2010 에 임명되었습니다 의 임기는 14.58 년입니다. 총 연간 보상은 $ 18.93M, 4.6% 로 구성됩니다. 4.6% 급여 및 95.4% 보너스(회사 주식 및 옵션 포함). 는 $ 695.59M 가치에 해당하는 회사 주식의 3.41% 직접 소유합니다. 695.59M. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 4.6 년입니다.

주요 정보

John Oyler

최고 경영자

US$18.9m

총 보상

CEO 급여 비율4.6%
CEO 임기14.7yrs
CEO 소유권3.9%
경영진 평균 재임 기간2.4yrs
이사회 평균 재임 기간4.4yrs

최근 관리 업데이트

Recent updates

BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat

Aug 22

Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts

Aug 14
Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts

BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth

Aug 09
BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

Jun 21

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

May 30
We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

Apr 21
Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

Mar 08

BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Jan 31
BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

Oct 16
Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?

Jul 11
Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?

Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

Jun 19
Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)

Apr 17
Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)

A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)

Mar 24
A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)

CEO 보상 분석

John Oyler 의 보수는 BeiGene 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$524m

Mar 31 2024n/an/a

-US$784m

Dec 31 2023US$19mUS$871k

-US$882m

Sep 30 2023n/an/a

-US$959m

Jun 30 2023n/an/a

-US$2b

Mar 31 2023n/an/a

-US$2b

Dec 31 2022US$18mUS$800k

-US$2b

Sep 30 2022n/an/a

-US$2b

Jun 30 2022n/an/a

-US$2b

Mar 31 2022n/an/a

-US$2b

Dec 31 2021US$17mUS$740k

-US$1b

Sep 30 2021n/an/a

-US$1b

Jun 30 2021n/an/a

-US$1b

Mar 31 2021n/an/a

-US$1b

Dec 31 2020US$14mUS$696k

-US$2b

Sep 30 2020n/an/a

-US$2b

Jun 30 2020n/an/a

-US$1b

Mar 31 2020n/an/a

-US$1b

Dec 31 2019US$13mUS$675k

-US$949m

Sep 30 2019n/an/a

-US$829m

Jun 30 2019n/an/a

-US$665m

Mar 31 2019n/an/a

-US$737m

Dec 31 2018US$28mUS$650k

-US$674m

Sep 30 2018n/an/a

-US$505m

Jun 30 2018n/an/a

-US$243m

Mar 31 2018n/an/a

-US$147m

Dec 31 2017US$10mUS$515k

-US$93m

보상 대 시장: John 의 총 보상 ($USD 18.93M )은 US 시장( $USD 13.21M ).

보상과 수익: 회사가 수익성이 없는 동안 John 의 보상이 증가했습니다.

CEO

John Oyler (56 yo)

14.7yrs

테뉴어

US$18,925,730

보상

Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009....

리더십 팀

이름위치테뉴어보상소유권
John Oyler
Co-Founder14.7yrsUS$18.93m3.91%
$ 908.4m
Xiaobin Wu
President & COO6.3yrsUS$11.00m0.055%
$ 12.9m
Xiaodong Wang
Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder14.7yrsUS$4.42m0.82%
$ 191.5m
Chan Lee
General Counsel & Senior VP2.2yrsUS$4.05m0.018%
$ 4.2m
Wang Lai
Global Head of R&Dno dataUS$7.32m0.13%
$ 29.9m
Aaron Rosenberg
CFO & Principal Financial Officerless than a year데이터 없음데이터 없음
Titus Ball
VP & Chief Accounting Officerless than a year데이터 없음0.0033%
$ 775.6k
Liza Heapes
Head of Investor Relationsno data데이터 없음데이터 없음
Yang Ji
Chief Compliance Officerless than a year데이터 없음데이터 없음
Yan Qi
Senior VP & Head of Public Affairs - Greater China3.7yrs데이터 없음데이터 없음
Jason Radford
Senior Vice President of Strategy & Corporate Development1.6yrs데이터 없음데이터 없음
Mark Lanasa
Senior VP & Chief Medical Officer for Solid Tumors2.6yrs데이터 없음데이터 없음

2.4yrs

평균 재임 기간

53.5yo

평균 연령

경험이 풍부한 관리: BGNE 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
John Oyler
Co-Founder13.9yrsUS$18.93m3.91%
$ 908.4m
Xiaodong Wang
Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder8.6yrsUS$4.42m0.82%
$ 191.5m
Steven Young
Acting Head of Medicinal Chemistry & Member of Scientific Advisory Board3.4yrs데이터 없음데이터 없음
Michael Goller
Independent Non-Executive Director & Member of the Scientific Advisory Committee9.4yrsUS$481.92k0.0034%
$ 784.9k
Donald Glazer
Independent Non-Executive Director11.6yrsUS$480.80k0.20%
$ 45.4m
Corazon Sanders
Independent Non-Executive Director & Member of Scientific Advisory Committee4.1yrsUS$501.55k0.0022%
$ 501.6k
Anthony Hooper
Independent Non-Executive Director4.7yrsUS$513.15k0.0027%
$ 629.3k
Shalini Sharp
Directorno data데이터 없음데이터 없음
Alessandro Riva
Co-Chairman of Scientific Advisory Committee & Independent Non-Executive Director2.6yrsUS$491.67k0.0021%
$ 497.0k
Olivier Brandicourt
Independent Non-Executive Directorless than a year데이터 없음0%
$ 0
Ranjeev Krishana
Independent Lead Director9.9yrsUS$487.05k0.0034%
$ 784.9k
Margaret Han Dugan
Member of Scientific Advisory Board & Independent Non-Executive Director2.6yrsUS$510.55k0.0021%
$ 497.0k

4.4yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: BGNE 의 이사회는 경험(평균 재직 기간 4.6 년)으로 간주됩니다.